CRST and Kancera AB signed a contract for a First-in-human trial with KAND145 CRST and Kancera AB entered into a contract for a First-in-human trial of KAND145, Kancera’s second generation fractalkine blocking drug candidate, primarily intended for cancer indications. Kancera…


CRST has appointed Petri Vainio as the CRST’s new Chief Scientific Officer CRTS is pleased to announce that company has appointed MD, PhD, Adjunct Professor of Pharmacology and Drug development Petri Vainio as the CRST’s new Chief Scientific Officer starting…
Recent Posts
- LINK Medical AS acquires Finnish clinical research service company CRST Oy.
- CRST and Kancera AB signed a contract for a First-in-human trial with KAND145
- CRST has appointed Petri Vainio as the CRST’s new Chief Scientific Officer
- CRST’s scientific team contributed in a study evaluating an ASO in mild Alzheimer’s disease
- Lihavuuden lääkehoidossa kohti mullistusta
Recent Comments
No comments to show.